When Ana Martinez finished her initial chemotherapy in Silver Spring, Maryland, doctors told her the cancer was stable—but the fight wasn’t over. Now, a new FDA-approved treatment offers patients like her a stronger chance to keep the disease at bay. On October 7, 2026, the U.S. Food and Drug Administration approved tucatinib—sold as Tukysa—combined with trastuzumab and pertuzumab, for adults with advanced HER2-positive breast cancer who’ve responded to initial therapy.
This approval matters because HER2-positive breast cancer is aggressive, and when it spreads, options have been limited. Now, patients who’ve completed 4 to 8 cycles of initial treatment with trastuzumab, pertuzumab, and a taxane can continue with this new maintenance regimen to delay the cancer’s return. The decision focused on a critical question: can we extend the time patients live without their cancer worsening? The answer, from a rigorous trial involving 654 people, was a clear yes.
The study, called HER2CLIMB-05, randomly assigned patients to receive either tucatinib or a placebo, along with continued trastuzumab and pertuzumab. The results were striking: those on tucatinib went a median of 24.9 months without disease progression, compared to 16.3 months for those on the placebo. That’s an 8.6-month gain—nearly three extra quarters of life with stability. The statistical strength behind this finding was solid, with a hazard ratio of 0.64 and a p-value less than 0.0001, meaning the result is highly unlikely to be due to chance.
The impact is personal and profound. For patients with a diagnosis that once carried a grim outlook, this regimen offers more time—time to plan, to travel, to be with loved ones. While overall survival data are still maturing, the delay in progression is a meaningful victory. The treatment does come with risks: the FDA includes a boxed warning for liver toxicity, and patients may experience diarrhea or elevated creatinine levels, though kidney function often remains unaffected.
Tucatinib is taken as a 300 mg pill twice daily, paired with ongoing infusions or subcutaneous injections of trastuzumab and pertuzumab. The approval reflects not just scientific progress, but a growing emphasis on maintenance therapy—keeping cancer in check, much like managing a chronic condition. As research continues, this approach could become a blueprint for other cancers.
For patients like Ana, the future feels different. Not cured—yet—but steadier, more hopeful. And in the world of cancer care, that kind of progress is worth celebrating.